Literature DB >> 16261276

Simplified pulmonary vasodilatory testing in the cardiac catheterization laboratory with nasal cannula nitric oxide.

M Scheurer1, V Bandisode1, A M Atz2.   

Abstract

In patients with pulmonary hypertension, pulmonary vasodilator testing with inhaled nitric oxide (NO) during cardiac catheterization provides valuable data for defining future care plans. Previously, the use of delivery systems for spontaneously breathing individuals required a tight-fitting seal by face mask and an approved delivery and dilution device. We hypothesized that a simplified delivery system using nasal cannula could be utilized to effectively deliver NO during cardiac catheterization. We developed a simple delivery system to deliver through a nasal cannula a concentration of NO at 50 ppm at the nares along with supplemental oxygen (O2) via face tent. We prospectively employed this system for 10-minute intervals on 11 patients (age range, 7 months to 41 years) with pulmonary hypertension undergoing scheduled cardiac catheterization. Mean pulmonary artery pressure (PAp) decreased from 62 mmHg (range, 38-99) at room air testing to 45 mmHg (range, 36-91) with the addition of NO plus O2 (p = 0.014). Pulmonary vascular resistance (PVR) decreased from 11.6 U.m2 (range, 4.5-43.4) to 6.3 U.m2 (range, 2.0-34.2) (p = 0.001). A response of 20% or more reduction in PVR was seen in all 11 patients. The initial ratio of pulmonary to systemic vascular resistance (Rp:Rs) was 0.49 (range, 0.25-3.5) and decreased to 0.35 (range 0.1-2.6) (p = 0.002). No adverse side effects were noted. We found this NO delivery system to be a simple and effective method of pulmonary vasodilatory testing that may have wide applicability in the cardiac catheterization laboratory.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16261276     DOI: 10.1007/s00246-005-1026-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  6 in total

1.  Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation.

Authors:  I Adatia; S Perry; M Landzberg; P Moore; J E Thompson; D L Wessel
Journal:  J Am Coll Cardiol       Date:  1995-06       Impact factor: 24.094

2.  Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing.

Authors:  A M Atz; I Adatia; J E Lock; D L Wessel
Journal:  J Am Coll Cardiol       Date:  1999-03       Impact factor: 24.094

3.  Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension.

Authors:  D D Ivy; J L Griebel; J P Kinsella; S H Abman
Journal:  J Pediatr       Date:  1998-09       Impact factor: 4.406

Review 4.  Effects of low doses of inhaled nitric oxide combined with oxygen for the evaluation of pulmonary vascular reactivity in patients with pulmonary hypertension.

Authors:  E Azeka; J O Costa Auler; L Kajita; A C Alliman; J A A Franchini Ramires; M Ebaid
Journal:  Pediatr Cardiol       Date:  2002 Jan-Feb       Impact factor: 1.655

5.  Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension.

Authors:  D L Wessel; I Adatia; J E Thompson; P R Hickey
Journal:  Crit Care Med       Date:  1994-06       Impact factor: 7.598

6.  Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group.

Authors:  David T Balzer; Henry W Kort; Ronald W Day; Howard M Corneli; John P Kovalchin; Bryan C Cannon; Stephen F Kaine; D Dunbar Ivy; Steven A Webber; Abraham Rothman; Robert D Ross; Sanjeev Aggarwal; Masato Takahashi; J Deane Waldman
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

  6 in total
  2 in total

1.  Perioperative management of pulmonary hypertension in children with critical heart disease.

Authors:  Ronald A Bronicki
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-10

2.  Paradoxical relationship between B-type natriuretic peptide and pulmonary vascular resistance in patients with ventricular septal defect and concomitant severe pulmonary hypertension.

Authors:  Manatomo Toyono; Kenji Harada; Masamichi Tamura; Mieko Aoki-Okazaki; Shunsuke Shimada; Jun Oyamada; Goro Takada
Journal:  Pediatr Cardiol       Date:  2007-09-05       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.